The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The promise of bispecific antibodies in the treatment of NHL
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, shares his excitement for the advent of bispecific antibodies for the treatment of non-Hodgkin lymphoma (NHL), highlighting their advantages over CAR-T therapies and commenting on where they could be incorporated in the treatment algorithm of NHL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche: Honoraria, Research Funding; Novartis: Other: Travel support, Research Funding.
